PRESS-RELEASE ·Filed May 1, 2026
Press release · Earnings
Actionable Insight ◆ Mixed
Regulatory path for ersodetug remains uncertain; watch for FDA feedback on submitted data package. Stock likely to be volatile on any news regarding potential approval pathway.
Final — all horizons settled through T+60d
RZLT ▲ +49.09% at T+60d
NEUTRAL call +49.09% · α vs SPY +46.02% · entry $3.30 → $4.92
T+1d
0.00%
call 0.00% · α +0.34%
$3.30
settled 6mo ago
T+5d
-6.36%
call -6.36% · α -8.71%
$3.09
settled 6mo ago
T+20d
+9.39%
call +9.39% · α +4.11%
$3.61
settled 5mo ago
T+60d
+49.09%
call +49.09% · α +46.02%
$4.92
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Rezolute released expanded Phase 3 sunRIZE study data showing clinically meaningful glycemic improvements on multiple CGM endpoints, despite the study missing its primary endpoint. The FDA has requested broader data to inform next steps, creating regulatory uncertainty.
Key Facts
- Phase 3 sunRIZE study missed primary endpoint (hypoglycemia events by SMBG) at Week 24
- Additional CGM-based analyses showed >50% reduction in time in hypoglycemia and increased normoglycemia across multiple timepoints
- All 59 study completers entered open-label extension; 57 remain with 6-24 months cumulative ersodetug exposure
- FDA acknowledged study challenges and requested comprehensive data submission to determine next steps
Financial Impact
No financial figures disclosed in filing
Risk Factors
- FDA may require additional trials if data is insufficient
- Competing therapies for congenital hyperinsulinism
- Cash burn rate without revenue could necessitate future financing
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (16 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286124 |
13 reports for RZLT
80% Hit rate @ T+20 Went positive at some point 5 of 5 best @ T+60▲ +26.00%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEF 14A | $3.86 | awaiting T+20 | — | $3.82 (−1.04%) |
Oct 14, 2026 12d ago | 8-K | $3.90 | awaiting T+20 | — | $3.82 (−2.05%) |
Oct 5, 2026 21d ago | 8-K | $4.33 | awaiting T+20 | — | $3.82 (−11.78%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $3.82 (+2.05%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $3.82 (+2.05%) |
Jul 21, 2026 13w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $3.82 (−24.95%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $3.82 (−1.04%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $3.82 (−15.30%) |
Jun 2, 2026 20w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $3.82 (−4.50%) |
May 12, 2026 23w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $3.82 (+14.71%) |
Showing 10 of 13
US Market Status
Market Closed — Opens in 4h 23m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers